Uricosuric

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 2952 Experts worldwide ranked by ideXlab platform

Hiroshi Koga - One of the best experts on this subject based on the ideXlab platform.

Takashi Dan - One of the best experts on this subject based on the ideXlab platform.

Robert P Hanzlik - One of the best experts on this subject based on the ideXlab platform.

Michel Burnier - One of the best experts on this subject based on the ideXlab platform.

  • Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients.
    Transplantation, 1998
    Co-Authors: Gianni Minghelli, Charles Seydoux, Jean-jacques Goy, Michel Burnier
    Abstract:

    Background. The angiotensin II receptor antagonist losartan is an effective antihypertensive agent with unique Uricosuric properties. This study evaluates the Uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia. Methods. The patients were randomized to receive losartan 50 mg once daily and enalapril 20 mg once daily for 4 weeks according to a double-blind crossover design. Office blood pressure, plasma uric acid levels, and urinary uric acid excretion were monitored throughout the study. Results. Plasma uric acid levels decreased significantly after 4 weeks of treatment with losartan (P

  • Uricosuric effect of the angiotensin ii receptor antagonist losartan in heart transplant recipients
    Transplantation, 1998
    Co-Authors: Gianni Minghelli, Charles Seydoux, Jean-jacques Goy, Michel Burnier
    Abstract:

    Background. The angiotensin II receptor antagonist losartan is an effective antihypertensive agent with unique Uricosuric properties. This study evaluates the Uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia. Methods. The patients were randomized to receive losartan 50 mg once daily and enalapril 20 mg once daily for 4 weeks according to a double-blind crossover design. Office blood pressure, plasma uric acid levels, and urinary uric acid excretion were monitored throughout the study. Results. Plasma uric acid levels decreased significantly after 4 weeks of treatment with losartan (P<0.05) but not with enalapril. On day 1 and after 1 month of treatment, a significant increase in uric acid excretion was observed only with losartan. Significant decreases in office systolic and diastolic blood pressures were obtained with enalapril but not with losartan. Conclusions. Losartan effectively lowers plasma uric acid levels in hyperuricemic heart transplant patients.

Yakov M Koen - One of the best experts on this subject based on the ideXlab platform.